Axial Biotech, Inc. is focused on the use of genetics and the development of minimally invasive, motion preserving implants to advance the diagnosis and treatment of diseases and deformities of the human spine. Axial is the first company to pursue DNA-based pre-symptomatic and prognostic tests for common spinal conditions which will augment current clinical and surgical practices. In its initial product development initiative, Axial has made significant progress towards the discovery of a location in the human genome that is associated with adolescent idiopathic scoliosis. In addition, Axial’s founders have developed five fusionless surgical devices (including the only such device currently being implanted in humans) that have the promise of expanding the current treatable scoliosis patient population by a factor of ten. Axial intends to use its proprietary genetic intellectual property in the development of bio-mechanical devices, and to apply its gene discovery/product development methodology to other spinal diseases.